Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Boehringer Ingelheim

Brain chemistry reveals psychiatry’s false divisions – new study

For decades, psychiatrists have treated psychosis as if it were separate conditions. People experiencing hallucinations and delusions might be diagnosed with schizophrenia, bipolar disorder, severe depression and related diagnoses, and receive completely different treatments based on diagnosis. But new research suggests this approach may be fundamentally flawed.

The Conversation

Silicosis is ruining the lungs of construction workers. An AI-powered breath test can detect it in minutes

Silicosis is an incurable but entirely preventable lung disease. It has only one cause: breathing in too much silica dust. This is a risk in several industries, including tunnelling, stone masonry and construction.

The Conversation

Foot-and-mouth disease vaccine supply deal secured

A major deal with a pharmaceutical company will ensure Australia has access to antigens and vaccines to defend itself against a foot-and-mouth disease outbreak.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Boehringer To Lay Off Salespeople Due To Slow Humira Biosimilar Sales

Boehringer Ingelheim announces layoffs due to poor biosimilar sales of Humira, emphasizing commitment to R&D for future growth.

Top News

Sanofi To Settle Around 4,000 Suits Over Zantac Cancer Allegations

Sanofi will settle around 4,000 claims alleging its heartburn medication, Zantac, is linked to cancer.

International Business Times

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Roll Call

Veeva Systems (VEEV) vs. Alcon (ALC) Earnings Watch: Which Medical Stock Is the Better Pick?

In the fast-paced world of healthcare, where aging population and technological leaps are driving significant growth in the sector, which of the two medical stocks, Veeva Systems (VEEV) and Alcon Inc. (ALC), could emerge as the better prescription for your portfolio? Let's find out….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

‘Like a bad dream’: Briton’s death in Spain heightens fears about painkiller Nolotil

The controversial painkiller is being cited in a growing number of deaths in Spain despite warnings about dangerous side-effects

The Guardian - UK

IBM wants to use its AI to help new antibody discoveries

IBM is know for its huge developments in AI and quantum, and is now investigating applications outside of technology?

TechRadar

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.